The Phosphate Content of Prescription Medication: A New Consideration

Background: Phosphate restriction is needed in most dialysis patients. The package inserts from some medications indicate that phosphate may be part of the excipient fraction of drugs. It is unclear whether its amount may be clinically significant since the phosphate content is unquantified. Methods...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic innovation & regulatory science 2015-11, Vol.49 (6), p.886-889
Main Authors: Sherman, Richard A., Ravella, Supriya, Kapoian, Toros
Format: Article
Language:English
Subjects:
Authorship
Drug dosages
Drug Safety and Pharmacovigilance
Generic drugs
Hemodialysis
Kidney diseases
Laboratories
Manufacturers
Patients
Pharmaceutical industry
Pharmacotherapy
Pharmacy
Prescription drugs
Product Development and Innovation: Original Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Phosphate restriction is needed in most dialysis patients. The package inserts from some medications indicate that phosphate may be part of the excipient fraction of drugs. It is unclear whether its amount may be clinically significant since the phosphate content is unquantified. Methods: We reviewed the package inserts for the branded formulations of the most widely used drugs at a dialysis chain. We measured the phosphate levels in a sample of the branded form of these drugs and some of their generic formulations. We also reviewed the available package inserts of 16 selected generic drug manufacturers for the presence of phosphate in drugs that were phosphate free in their branded formulation. Results: We identified 12 prescription products that contained phosphate, 9 of which contained clinically significant quantities (>10 mg per daily dose) notably in both branded and generic forms of amlodipine, lisinopril, paroxetine and bisoprolol. Phosphate was rarely present in a generic drug when its corresponding branded formulation was phosphate free. Conclusion: Commonly prescribed drugs may contain clinically important levels of phosphate.
ISSN:2168-4790
2168-4804
DOI:10.1177/2168479015592194